Published in Haematologica on April 04, 2012
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature (2014) 1.84
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One (2013) 1.17
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.06
Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway. Viruses (2013) 1.03
Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia. PLoS One (2015) 0.96
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica (2014) 0.91
Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. Haematologica (2015) 0.89
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.84
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med (2016) 0.83
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica (2016) 0.79
MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia (2016) 0.79
The genetics and molecular biology of T-ALL. Blood (2017) 0.78
Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia (2015) 0.78
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. Oncotarget (2016) 0.78
Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia. J Cell Mol Med (2014) 0.77
Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia (2015) 0.77
Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy. Blood (2016) 0.76
Mouse models for efficacy testing of agents against radiation carcinogenesis—a literature review. Int J Environ Res Public Health (2012) 0.76
Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor. BMC Cancer (2016) 0.75
Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia (2016) 0.75
Oncogenic PTEN functions and models in T-cell malignancies. Oncogene (2015) 0.75
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica (2016) 0.75
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J (2017) 0.75
Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes. Medicine (Baltimore) (2017) 0.75
Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing. Sci Rep (2017) 0.75
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature (2010) 13.82
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Tenets of PTEN tumor suppression. Cell (2008) 8.61
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Notch signaling in leukemia. Annu Rev Pathol (2008) 3.21
HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood (2005) 3.09
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol (2001) 2.87
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol (2009) 2.48
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood (2007) 2.29
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10
Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol (2000) 2.06
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res (2000) 1.79
Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet (2007) 1.65
The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood (2006) 1.63
PTEN gene alterations in lymphoid neoplasms. Blood (1998) 1.57
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia (2009) 1.45
NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res (2006) 1.42
Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet (2007) 1.39
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia (2007) 1.36
Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol (2004) 1.31
Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol (2005) 1.30
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia (2009) 1.23
Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol (2010) 1.22
FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol (2009) 1.12
Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet (2006) 1.11
PTEN: its deregulation and tumorigenesis. Biol Pharm Bull (2007) 0.94
Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica (2009) 0.82
Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med Oncol (2010) 0.80
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology (2006) 6.55
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Laser-capture microdissection. Nat Protoc (2006) 3.80
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell (2008) 2.78
No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: a prospective longitudinal study. J Pediatr Hematol Oncol (2002) 2.72
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst (2005) 2.63
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood (2012) 2.56
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol (2009) 2.54
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol (2009) 2.48
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Online focus groups as a tool to collect data in hard-to-include populations: examples from paediatric oncology. BMC Med Res Methodol (2009) 2.38
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood (2009) 2.19
Medical end-of-life decisions for children in the Netherlands. Arch Pediatr Adolesc Med (2005) 2.09
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy. Pediatr Blood Cancer (2012) 2.08
Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol (2009) 2.04
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood (2009) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
An investigation into the human serum "interactome". Electrophoresis (2004) 1.93
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics (2008) 1.88
In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol Sci (2006) 1.87
A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem (2007) 1.87
2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica (2006) 1.83
Shared care by paediatric oncologists and family doctors for long-term follow-up of adult childhood cancer survivors: a pilot study. Lancet Oncol (2008) 1.80
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood (2014) 1.80
WT1 mutations in T-ALL. Blood (2009) 1.75
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica (2010) 1.71
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem (2003) 1.69
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics (2003) 1.66
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood (2003) 1.65
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood (2011) 1.64
The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood (2006) 1.63
Proteomics of human breast ductal carcinoma in situ. Cancer Res (2002) 1.62
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr Blood Cancer (2009) 1.62
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett (2007) 1.58
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58
Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk Lymphoma (2013) 1.58
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58
Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer (2005) 1.57
Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res (2005) 1.55
Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer (2010) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase. Pediatr Blood Cancer (2011) 1.53